The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days

Date: October 1, 2025

Analyst: PhD, Life Sciences Research

Introduction: The Focus on Functional Longevity

This week's key developments in longevity science underscore a critical and accelerating shift away from merely extending lifespan toward interventions that actively restore or maintain *function*. The primary focus is on enhancing healthspan, with a particular emphasis on high-impact areas such as sensory perception, cognitive acuity, and physical mobility. The research emerging over the past seven days reveals a new understanding of age-related decline, recasting some aspects not as slow, inexorable degeneration, but as dynamic, rapid, and potentially reversible failures of cellular and systemic processes.

This report dissects five pivotal areas of progress that define the current state of the field:

1. **Metabolic Modulation:** Preclinical breakthroughs reveal how targeted metabolic interventions can rapidly reverse functional decline in vision and cognition, highlighting the fragility and plasticity of these systems.
2. **Senescence Biology:** New insights into the heterogeneity of senescent cells are providing a more nuanced understanding of their role in aging and refining the strategies for next-generation senolytic therapies.
3. **Clinical and Lifestyle Frameworks:** Immediately applicable strategies, from new models of geriatric care to the neuroprotective power of psychological well-being, promise to improve healthspan in current aging populations.
4. **Enabling Technologies:** The advent of sophisticated *ex vivo* models and powerful AI-driven research platforms is compressing discovery timelines from years to weeks,

fundamentally altering the pace of innovation.

5. **Regulatory Landscape:** Critical updates from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the National Institute on Aging (NIA) are shaping the translational pathway for future longevity therapeutics.

The convergence of these themes signals a maturing field where deep mechanistic understanding is increasingly paired with clear translational intent. For stakeholders in research, medicine, and investment, this week's findings highlight actionable therapeutic targets, validate new research paradigms, and provide a clearer view of the regulatory and practical hurdles that lie ahead on the path to extending functional human life.

Key Findings: New Interventions to Enhance Healthspan

The past week has seen significant progress across multiple domains of longevity science. The following table provides an executive summary of the most impactful discoveries, standardizing their core attributes to allow for rapid assessment and comparison. This dashboard distills complex research into a format designed for strategic prioritization, offering a critical tool for decision-makers in research and development, clinical practice, and investment.

Intervention /Discovery	Key Mechanism	Model System	Key Functional Outcome	Source Publication/ Institution	Translational Readiness Level (TRL)
PUFA Supplementation for Vision	Bypasses age-related ELOVL2 enzyme deficit, restoring retinal lipid composition.	Aged Mice	Reversal of functional vision decline (contrast sensitivity, rod recovery).	*Science Translational Medicine* / UC Irvine	TRL 2-3 (Preclinical)
High-Fat Diet Impact	Impaired brain	Mice	Rapid (4-day)	*Neuron* / UNC School	TRL 2-3

on Cognition	glucose utilization leads to hyperactivity of hippocampal CCK interneurons.		impairment of memory formation; reversible with fasting.	of Medicine	(Preclinical)
Senescent Cell Sub-targeting	G2-arrested senescent cells are more pro-inflammatory and more sensitive to senolytic drug ABT263.	Human Cell Culture	Enhanced clearance of a specific, more pathogenic senescent cell subpopulation.	*Aging-US* / Buck Institute, Johns Hopkins	TRL 1-2 (Basic Research)
Geriatric Fracture Care Model	Integrated, multidisciplinary "phase-of-care" approach guided by the "Geriatric 5 Ms".	Human Healthcare System Analysis	Proposed improvement in functional outcomes, reduced morbidity/mortality.	*Nature Aging* / JABSOM	TRL 8 (System Implementation)
"Purpose in Life" and Dementia Risk	Independent psychosocial factor associated with enhanced	Large Human Cohort (>13,000)	28% lower risk of developing cognitive impairment, independent of APOE4	*American Journal of Geriatric Psychiatry* / UC Davis	TRL 7 (Epidemiological Evidence)

	brain resilience.		status.		

Metabolic Regulation of Sensory and Cognitive Function

Two landmark preclinical studies this week have converged on the theme of metabolic fragility, demonstrating that critical age-related functional declines in the brain and eye may be rapid, reversible consequences of metabolic dysregulation rather than slow, structural decay.

PUFA Supplementation Reverses Age-Related Vision Decline

A study published in *Science Translational Medicine* by researchers at the University of California, Irvine, provides a powerful proof-of-concept for reversing age-related vision loss.[1] The work builds on the understanding that the gene

ELOVL2 is a key enzyme in the production of very-long-chain polyunsaturated fatty acids (VLC-PUFAs), which are essential for retinal health. The expression of *ELOVL2* declines with age, leading to a deficit of these critical lipids.[2]

The research team demonstrated that a single intravitreal injection of a specific VLC-PUFA, 24:5n-3, could bypass the age-related ELOVL2 enzyme deficiency and restore function in aged mice.[2] The functional outcomes were significant, with treated mice showing improved contrast sensitivity and faster recovery of rod photoreceptor responses after light exposure.[5] Molecular analysis confirmed these functional gains, revealing a partial rejuvenation of the retinal transcriptome and a reduction in the accumulation of age-related protein deposits, such as Apolipoprotein E (ApoE) and HTRA1, which are associated with macular degeneration.[4] Critically, the study showed that supplementation with the more common omega-3 fatty acid DHA alone was ineffective, highlighting the high specificity of the metabolic intervention required.[1] The translational relevance of this pathway was solidified by the identification of genetic variants in the human

ELOVL2 locus that are significantly associated with a faster progression of age-related macular degeneration (AMD), directly linking this mechanism to human disease.[1]

High-Fat Diet Rapidly Impairs Memory via Neuronal Hyperactivity

In a parallel development for cognitive health, research from the UNC School of Medicine published in *Neuron* reveals that a high-fat diet can disrupt memory circuits in mice with astonishing speed—within just four days, long before the onset of obesity or other systemic metabolic syndromes.[7] The study elucidates a precise mechanism: the high-fat diet impairs the brain's ability to utilize glucose as an energy source. This localized energy deficit causes a specific group of inhibitory neurons in the hippocampus, known as cholecystokinin (CCK) interneurons, to become hyperactive, disrupting the delicate electrical balance required for memory processing and consolidation.[7]

The functional consequence in the animal models was impaired memory performance in behavioral tests.[7] Most importantly, the study demonstrated that this cognitive deficit is not permanent but is dynamically reversible. Interventions that restored the brain's metabolic state, such as intermittent fasting or other methods to improve glucose availability, successfully calmed the overactive CCK interneurons and fully restored memory function.[7] This finding reframes diet-induced cognitive impairment as a state of reversible metabolic stress rather than irreversible damage.

The convergence of these two distinct studies points to a powerful emerging concept in geroscience: that key functional declines in aging can be manifestations of *metabolic fragility*. The rapid onset of cognitive deficits in the diet study and the swift reversal of vision decline in the PUFA study challenge the traditional view of age-related decay as a slow, intractable accumulation of structural damage. Instead, they suggest that in some contexts, the aging brain and eye are not failing solely due to wear and tear, but because their ability to buffer metabolic stress—whether from a poor diet or an enzymatic decline—has become compromised. This opens a new and highly attractive therapeutic axis focused on "metabolic rejuvenation." Rather than aiming for the high bar of reversing decades of structural damage, a parallel strategy of developing therapies that restore metabolic homeostasis and resilience in specific tissues could offer a faster path to market and a more immediate improvement in the functional health of aging individuals.

Advancing Senolytic Strategies through Understanding Cellular Heterogeneity

Senolytics, drugs that selectively clear senescent cells, are a leading class of longevity

therapeutics. However, clinical results have been mixed, suggesting a gap in our understanding of their mechanism of action *in vivo*.[12] A new study published in

Aging-US from a collaboration between the Buck Institute for Research on Aging and Johns Hopkins University provides a critical piece of this puzzle, offering the first functional evidence that distinct subpopulations of senescent cells respond differently to senolytic drugs.[13]

Using high-content imaging analysis of human cells, the researchers discovered that the cell cycle state at the time of senescence induction creates functionally distinct cell types. Specifically, cells that become senescent while arrested in the G2 phase of the cell cycle exhibit a more aggressive and pathogenic phenotype: they express higher levels of senescence markers, secrete more of the pro-inflammatory cytokine Interleukin-6 (IL-6), and, most importantly, are significantly more sensitive to clearance by the BCL-2 family inhibitor senolytic drug ABT263 (Navitoclax) when compared to senescent cells arrested in the G1 phase.[15]

This discovery has profound implications for the entire field of senotherapeutics. It suggests that the prevailing "one-size-fits-all" approach to senolytic drug development is likely flawed. The partial or inconsistent efficacy seen in some studies could be explained if the drug being tested is highly effective against one pathogenic subpopulation but completely ineffective against another that is also contributing to the disease pathology.[15] The success of future senolytic therapies will therefore depend on developing strategies that account for this heterogeneity.

This finding necessitates a paradigm shift in both drug discovery and clinical trial design for senolytics. Drug discovery platforms must now evolve to screen for compounds that are effective against a diverse panel of well-characterized senescent subtypes, rather than a single generic model. This will likely lead to the development of either broad-spectrum senolytics or, more probably, rationally designed "senolytic cocktails" that can clear multiple, distinct senescent cell populations from a tissue. Furthermore, this work highlights the urgent need for companion diagnostics. To effectively treat patients, it may become necessary to first characterize the "seno-profile" of their target tissue to identify the dominant senescent subtypes present and match them with the most effective senolytic therapy. Companies in the senotherapeutics space that can demonstrate a clear strategy for addressing this heterogeneity will hold a significant competitive advantage.

Immediately Applicable Strategies for Improving Healthspan

While molecular interventions represent the future of longevity medicine, research from the past week also highlights powerful systemic and psychosocial strategies that can be

implemented today to improve functional healthspan in aging populations.

A New Clinical Framework for Geriatric Fracture Care

A correspondence published in *Nature Aging* by researchers at the John A. Burns School of Medicine (JABSOM) proposes a new, integrated "phase-of-care" model to improve outcomes for older adults suffering from fragility fractures.[19] Fragility fractures, often from falls, are a leading cause of loss of function, independence, and mortality in the elderly, yet post-fracture care remains highly fragmented.[19] The proposed model advocates for a multidisciplinary team—including geriatricians, orthopedic surgeons, physical therapists, and social workers—to co-manage patients across four distinct phases: primary prevention, acute management, secondary prevention, and rehabilitation.[19] This approach is guided by the established "Geriatric 5 Ms" framework: Mind, Mobility, Medications, Multicomplexity, and "What Matters Most" to the patient.[19] This framework is supported by a body of evidence indicating that such integrated orthogeriatric models lead to superior outcomes, including lower mortality rates, fewer in-hospital complications, and better long-term functional recovery compared to standard care.[21]

Neuroprotective Effects of "Purpose in Life"

On the cognitive front, a large-scale, long-term study published in the *American Journal of Geriatric Psychiatry* provides compelling evidence for the neuroprotective effects of a strong sense of purpose.[24] Researchers from UC Davis followed more than 13,000 adults for up to 15 years and found that individuals reporting a higher purpose in life had a 28% lower risk of developing cognitive impairment, including mild cognitive impairment and dementia.[26] The most crucial aspect of this finding is its robustness; the protective effect was consistent across diverse racial and ethnic groups and, importantly, remained statistically significant even after controlling for known risk factors such as education level, depressive symptoms, and the presence of the high-risk

APOE4 gene.[24] This suggests that a sense of purpose is not merely a proxy for other healthy behaviors but is an independent psychological factor that enhances the brain's resilience to age-related pathology.

These two developments highlight the immense and immediate potential of systemic and psychosocial interventions. While they may seem "low-tech" compared to gene editing or

cellular reprogramming, their impact on population healthspan can be enormous due to their scalability and accessibility. The geriatric fracture model addresses a primary driver of functional decline at the healthcare system level, while cultivating a sense of purpose addresses one of the most feared aspects of aging at the individual and community level. This points to a significant market and public health opportunity. For healthcare providers, adopting integrated care models can reduce the substantial long-term costs associated with disability and institutionalization.[20] For the wellness and digital health sectors, developing evidence-based programs to help older adults find and engage in purposeful activities—such as volunteering, mentorship, or new learning—represents a newly validated avenue for promoting cognitive health and well-being.[26]

Early-Stage Research vs. Clinical Application: The Translational Pipeline

The discoveries of the past week clearly illustrate the bifurcated nature of progress in the longevity field, with advances occurring simultaneously on two distinct tracks: foundational preclinical research and near-term clinical or public health strategy.

Foundational Preclinical Breakthroughs (TRL 1-3)

This category comprises discoveries that provide novel mechanistic insights and identify new therapeutic targets but require substantial further validation before they can be applied in humans. The PUFA/vision and diet/cognition studies fall squarely into this group. They are powerful proofs-of-concept in animal models that validate specific metabolic pathways as drivers of functional decline and, crucially, demonstrate the principle of reversibility.[1]

However, the path to translation is long. Key questions must be answered before these findings can become therapies. For the vision-restoring VLC-PUFA, a non-invasive delivery method must be developed; while intravitreal injection is effective in mice, a systemic or oral formulation that can achieve therapeutic concentrations in the human retina would be required for broad application. For the diet-induced cognitive impairment, rigorous human trials are needed to determine the optimal dosage, timing, and long-term safety of interventions like intermittent fasting to produce a reliable therapeutic effect. These discoveries represent the high-risk, high-reward future of molecular longevity medicine, likely a decade or more from becoming approved treatments.

Insights for Near-Term Clinical & Public Health Strategy (TRL 7-9)

This category includes findings derived from human data that can be implemented into clinical practice or public health policy on a much shorter timeline. The proposed geriatric fracture care model and the "purpose in life" study are prime examples. The fracture care model is essentially a set of evidence-based best practices that can be adopted by healthcare systems immediately, with data suggesting it will improve patient outcomes and potentially reduce long-term costs.[19] Similarly, the data on purpose in life provides a strong evidentiary foundation for clinicians and public health organizations to actively recommend and facilitate activities that foster social engagement, goal-setting, and a sense of meaning for older adults.[26] These interventions represent the actionable "present" of healthy aging.

A comprehensive strategy for promoting longevity must therefore embrace both tracks. Focusing exclusively on moonshot molecular interventions ignores the massive and immediate healthspan gains that are available from optimizing current clinical systems and implementing evidence-based behavioral and psychosocial programs. This suggests that investors and policymakers should adopt a "portfolio" approach to longevity. A portion of investment must continue to target high-risk, high-reward basic science. However, significant capital and policy efforts should also be directed toward funding the implementation science needed to scale up proven systemic and behavioral interventions that can deliver immediate returns in population healthspan and reduced healthcare burden.

Technological Tools Accelerating Discovery

The pace of discovery in geroscience is being fundamentally accelerated by the development of novel technological platforms. Two announcements this week exemplify this trend, showcasing a new synergy between advanced biological models and artificial intelligence.

Advanced *Ex Vivo* Modeling: Observing Hearing Loss in a Dish

Researchers at The Rockefeller University have achieved a major technological breakthrough by successfully keeping a segment of a mammalian cochlea alive and functional outside the

body for the first time.[28] The work, reported in

PNAS and *Hearing Research*, overcomes a long-standing barrier in auditory science caused by the cochlea's fragility and inaccessibility within the skull.[28]

The technology consists of a custom-designed chamber that continuously perfuses the tiny tissue sliver with two distinct, nutrient-rich fluids (endolymph and perilymph) while maintaining its native temperature and electrical potential, precisely mimicking the *in vivo* environment.[29] Using this platform, the scientists were able to play sounds to the tissue and directly observe the intricate biomechanical responses of the sensory hair cells. This enabled them to provide the first direct evidence for a unifying biophysical principle of hearing known as the Hopf bifurcation, confirming that the auditory system operates at a critical tipping point between stability and oscillation to amplify faint sounds.[28] This platform now opens the door for high-throughput screening of compounds aimed at protecting or regenerating hair cells to combat age-related hearing loss.

AI-Driven Research Cycles: Compressing Discovery Timelines

In the computational domain, the startup Biostate AI, in collaboration with Professor David Sinclair's laboratory at Harvard Medical School, has launched K-Dense Beta, a multi-agent AI system designed to autonomously manage entire research cycles.[32] A recent preprint paper details its first major success: the development of a novel, "uncertainty-aware" transcriptomic aging clock in just a few weeks—a process that would typically take a team of human researchers months or even years.

The K-Dense platform is not a single algorithm but a suite of specialized AI agents that collaborate to perform complex tasks, including experimental design, literature review, and massive-scale data analysis. In this project, the system analyzed a dataset of over 600,000 RNA expression profiles, intelligently filtering it down to 60,000 high-quality samples and identifying 5,000 key genes from over 50,000 possibilities to build its clock.[32] A key innovation is that the resulting aging clock provides not only a prediction of biological age but also a confidence score for that prediction. This "uncertainty awareness" is a critical feature for clinical translation, where understanding the reliability of a biomarker is paramount.[32]

These two advancements are not isolated; they represent two halves of a powerful new discovery engine. Advanced, high-fidelity biological models like the *ex vivo* cochlea are capable of generating enormous, complex, high-dimensional datasets. AI platforms like K-Dense are precisely the tools needed to analyze these datasets at scale and speed, extract meaningful patterns, and generate new, testable hypotheses. This creates a closed-loop, accelerated research cycle: the biological model generates data, the AI analyzes it to produce

a new hypothesis, and that hypothesis is then immediately tested back in the model. The competitive advantage in biopharma R&D is thus shifting. It is no longer defined solely by a proprietary molecule or biological insight, but by the ability to build and integrate these high-throughput model systems with powerful AI analytics platforms. This creates an R&D "flywheel" that can outpace competitors, making investment in these enabling "picks and shovels" of longevity research a highly strategic priority.

Ethical and Practical Considerations

As the science of longevity accelerates, it is crucial to address the parallel challenges in regulation, ethics, and equity to ensure that discoveries are translated into safe, effective, and accessible interventions.

Navigating the Regulatory Pathway for Advanced Longevity Therapeutics

This week, the FDA released several draft guidance documents that are highly relevant to the future of longevity medicine, particularly for Cellular and Gene Therapy (CGT) products.[33] The guidance documents signal the agency's proactive stance in building a regulatory framework for the complex, potentially permanent interventions emerging from the field. Key provisions include an emphasis on the need for robust, long-term post-approval data collection to monitor safety and efficacy, acknowledging the unique nature of these therapies. The FDA also provided recommendations for sponsors to use innovative clinical trial designs, especially for therapies targeting small populations or rare diseases, an approach that could be adapted for trials targeting specific genetic drivers of aging.[33] For developers, this signals a clear regulatory expectation for comprehensive long-term patient follow-up and encourages early engagement with the agency on novel trial methodologies.

The Ethics of Nutraceuticals and Functional Foods

The promising results from the PUFA/vision study highlight the potential of specific nutrients to act as powerful therapeutic agents.[1] This brings the long-standing ethical and practical

challenges of the dietary supplement market into sharp focus. Unlike pharmaceutical drugs, dietary supplements do not require pre-market approval from the FDA for safety or efficacy.[34] This regulatory gap often leads to significant issues with product quality, purity, inconsistent dosing, and misleading health claims, creating potential risks for consumers who may be self-treating serious conditions.[34] If the specific VLC-PUFA identified in the vision study were to be marketed as a supplement, there would be no regulatory mechanism to ensure that commercial products contain the correct, biologically active molecule at an effective and safe dosage. This creates a significant gap between a promising scientific discovery and its reliable application for public benefit.

Accessibility and Equity in Longevity Interventions

The findings from the past week also present a stark contrast in the potential accessibility of different types of longevity interventions. Advanced therapies, such as a potential CGT or a medically administered PUFA injection for vision, are likely to be complex, high-cost medical products, potentially accessible only to a few. In contrast, the interventions with the most immediate applicability are far more equitable. The implementation of improved geriatric care models is a health systems challenge but is fundamentally about optimizing processes, not deploying expensive new technologies.[19] Similarly, promoting a "purpose in life" is a public health and community-level initiative that is virtually free and universally accessible.[24]

As the science accelerates, a "governance gap" is widening between what is scientifically possible, what is commercially viable, and what is ethically and equitably implemented. The current system is well-optimized for the development and regulation of patentable, high-margin drugs, as evidenced by the proactive FDA guidance on CGTs. However, it struggles to validate and implement evidence-based, non-pharmacological interventions, whether they are specific nutrients, new models of clinical care, or psychosocial programs. This points to a critical need for new models of validation and implementation. Potential solutions could include a new regulatory category for "medical foods" or "evidence-based nutraceuticals" that requires a streamlined but rigorous approval path, or the formation of public-private partnerships dedicated to funding the implementation science needed to scale up proven models of care across health systems.

Future Directions and Strategic Outlook

The developments of the past seven days provide a clear trajectory for the longevity field,

highlighting a convergence of molecular precision, technological acceleration, and a holistic view of healthspan.

The Rise of "Functional Geroscience"

The week's preclinical findings will catalyze a wave of research focused on the metabolic underpinnings of functional decline. The immediate future will see efforts to validate the role of the ELOVL2 pathway in other aging tissues beyond the retina and to initiate screening for small molecules or nutraceuticals that can safely modulate the activity of hippocampal CCK interneurons. These steps are critical for moving these discoveries from mechanistic insights to actionable therapeutic targets. This focus on restoring function by correcting specific metabolic deficits represents a maturing subfield that can be termed "functional geroscience."

The AI-Biology Symbiosis

The successful deployment of the K-Dense AI platform is a watershed moment, demonstrating the power of AI to not just analyze data but to autonomously drive a research project from start to finish.[32] The next one to two years will likely see a proliferation of similar AI-driven research platforms applied to other large-scale aging datasets, such as the UK Biobank. The true transformative potential lies in the synergy between these AI tools and new high-throughput biological models, like the

ex vivo cochlea. This combination will create a rapid, iterative R&D cycle, dramatically shortening the timeline for identifying and validating new interventions. The future of biological discovery will involve AI not only analyzing the results of an experiment but actively designing the next, most informative one to perform.

A Multi-Pillar Approach to Healthspan

Ultimately, the most impactful takeaway from this week is the powerful reinforcement of a multi-pillar strategy for extending functional life. The future of longevity medicine is not a single "magic bullet" but a rationally combined, personalized approach that includes:

- **Precision Molecular Interventions:** Targeting specific, validated pathways of aging, such as the ELOVL2 lipid pathway or distinct subpopulations of senescent cells.
- **Optimized Clinical Systems:** Implementing evidence-based, integrated care models, such as the one proposed for geriatric fractures, to improve outcomes and preserve function within our existing healthcare infrastructure.
- **Evidence-Based Lifestyle and Psychosocial Factors:** Systematically harnessing the profound and scientifically validated power of diet, purpose, social connection, and other behavioral factors to enhance resilience against age-related decline.

The developments of the past seven days paint a picture of a field that is rapidly moving from broad theories of aging to specific, testable, and often reversible mechanisms of functional decline. The key challenge ahead is not just one of scientific discovery, but of building the clinical, regulatory, and social infrastructure required to translate these diverse and powerful discoveries into tangible, equitable, and widespread gains in human healthspan.

Works cited

1. Science Translational Medicine - Medical Xpress, accessed October 1, 2025, https://medicalxpress.com/journals/science-translational-medicine/
2. Reversing Age-Related Vision Decline | UC Irvine School of Medicine, accessed October 1, 2025, https://medschool.uci.edu/news/reversing-age-related-vision-decline
3. Researchers Identify Gene with Functional Role in Aging of Eye - UC San Diego Today, accessed October 1, 2025, https://today.ucsd.edu/story/researchers-identify-gene-with-functional-role-in-aging-of-eye
4. Polyunsaturated Fatty Acid - mediated Cellular Rejuvenation for Reversing Age-related Vision Decline - PMC - PubMed Central, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11244954/
5. Rescue of Age-related Vision Decline: Targeting ELOVL2-Mediated Fatty Acid Elongation, accessed October 1, 2025, https://iovs.arvojournals.org/article.aspx?articleid=2797610
6. Polyunsaturated Fatty Acid - mediated Cellular Rejuvenation for Reversing Age-related Vision Decline - PubMed, accessed October 1, 2025, https://pubmed.ncbi.nlm.nih.gov/39005302/
7. Junk food can scramble memory in just 4 days - ScienceDaily, accessed October 1, 2025, https://www.sciencedaily.com/releases/2025/09/250927031249.htm
8. Published in Neuron, new research demonstrates how a high-fat diet, even short-term, can rapidly affect brain health, but there are ways to reverse this and prevent long-term cognitive decline. | UNC Neuroscience Center, accessed October 1, 2025, https://www.med.unc.edu/neuroscience/published-in-neuron-new-research-demonstrates-how-a-high-fat-diet-even-short-term-can-rapidly-affect-brain-health-but-there-are-ways-to-reverse-this-and-prevent-long-term-cognitive-decline/
9. Bingeing On Junk Food For Just 4 Days Can Damage Your Brain's Memory Hub,

Study Warns - Zee News, accessed October 1, 2025, https://zeenews.india.com/health/bingeing-on-junk-food-for-just-4-days-can-damage-your-brain-s-memory-hub-study-warns-2959260
10. Just 4 Days of Junk Food Can Rewire Your Brain's Memory Center, accessed October 1, 2025, https://scitechdaily.com/just-4-days-of-junk-food-can-rewire-your-brains-memory-center/
11. Fast food can do this damage to brain within 4 days: Study reveals how to reverse it | Health, accessed October 1, 2025, https://www.hindustantimes.com/lifestyle/health/fast-food-can-do-this-damage-to-brain-within-4-days-study-reveals-how-to-reverse-it-101758262319372.html
12. Senolytic therapy shows subtle impact on age-related bone health in women, accessed October 1, 2025, https://www.nia.nih.gov/news/senolytic-therapy-shows-subtle-impact-age-related-bone-health-women
13. Cell Cycle Status Alters Aging Cells' Senolytic Drug Response - Mirage News, accessed October 1, 2025, https://www.miragenews.com/cell-cycle-status-alters-aging-cells-senolytic-1538962/
14. heterogeneity Archives - Aging (Aging-US) Authors, accessed October 1, 2025, https://aging-us.net/tag/heterogeneity/
15. Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status during senescence induction - Aging-US, accessed October 1, 2025, https://www.aging-us.com/article/206299/text
16. Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status during senescence induction - PMC, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12422821/
17. Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status during senescence induction - Aging-US, accessed October 1, 2025, https://www.aging-us.com/article/206299
18. Senescent cell heterogeneity and responses to senolytic treatment are related to cell cycle status during cell growth arrest | Request PDF - ResearchGate, accessed October 1, 2025, https://www.researchgate.net/publication/381743351_Senescent_cell_heterogeneity_and_responses_to_senolytic_treatment_are_related_to_cell_cycle_status_during_cell_growth_arrest
19. JABSOM Student Advocates New Model for Caring for Aging Patients with Fractures, accessed October 1, 2025, https://jabsom.hawaii.edu/news-events/news/2025/09/philip-lee-published-in-nature-aging-for-fracture-care.html
20. (PDF) A phase-of-care approach to improve geriatric fracture care - ResearchGate, accessed October 1, 2025, https://www.researchgate.net/publication/395597198_A_phase-of-care_approach_to_improve_geriatric_fracture_care
21. Orthogeriatric model of care for hip fracture care evidence check - Agency for

Clinical Innovation, accessed October 1, 2025, https://aci.health.nsw.gov.au/__data/assets/pdf_file/0012/828579/ACI-Orthogeriatric-model-of-care-for-hip-fracture-care-evidence-check.pdf
22. Defining optimal orthogeriatric hip fracture care: a delphi consensus approach - PMC, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12014745/
23. Elderly adults with isolated hip fractures- orthogeriatric care versus standard care: Practice Management Guideline - The Eastern Association for the Surgery of Trauma, accessed October 1, 2025, https://www.east.org/education-resources/practice-management-guidelines/details/elderly-adults-with-isolated-hip-fractures-orthogeriatric-care-versus-standard-care
24. Life Purpose Linked to Lower Dementia Risk | Technology Networks, accessed October 1, 2025, https://www.technologynetworks.com/diagnostics/news/purpose-in-life-may-help-protect-against-dementia-404077
25. Purpose in Life Linked to 28% Lower Risk of Cognitive Impairment and Dementia, accessed October 1, 2025, https://scitechdaily.com/purpose-in-life-linked-to-28-lower-risk-of-cognitive-impairment-and-dementia/
26. Having a sense of purpose may protect against dementia - UC Davis Health, accessed October 1, 2025, https://health.ucdavis.edu/news/headlines/having-a-sense-of-purpose-may-protect-against-dementia/2025/08
27. Having a Purpose in Life Linked to Lower Dementia Risk - Neuroscience News, accessed October 1, 2025, https://neurosciencenews.com/life-purpose-alzheimers-29612/
28. First living cochlea outside the body shows how hearing really works | ScienceDaily, accessed October 1, 2025, https://www.sciencedaily.com/releases/2025/09/250929055003.htm
29. Researchers keep a mammalian cochlea alive outside the body for the first time, accessed October 1, 2025, https://www.rockefeller.edu/news/38213-researchers-keep-a-mammalian-cochlea-alive-outside-the-body-for-the-first-time/
30. Amplification through local critical behavior in the mammalian cochlea - PNAS, accessed October 1, 2025, https://www.pnas.org/doi/10.1073/pnas.2503389122
31. Researchers keep mammalian cochlea alive outside the body for first time and play sounds to it - Hearing Practitioner Australia, accessed October 1, 2025, https://hearingpractitionernews.com.au/researchers-keep-mammalian-cochlea-alive-outside-the-body-for-first-time-and-play-sounds-to-it/
32. New AI tool demonstrates potential to accelerate longevity research, accessed October 1, 2025, https://longevity.technology/news/new-ai-tool-demonstrates-potential-to-accelerate-longevity-research/
33. Health Care Week in Review | September 26, 2025 - Alston & Bird, accessed

October 1, 2025, https://www.alston.com/en/insights/publications/2025/09/health-care-week-in-review-september-26-2025
34. Regulatory and Ethical Issues with Dietary Supplements - ResearchGate, accessed October 1, 2025, https://www.researchgate.net/publication/12249013_Regulatory_and_Ethical_Issues_with_Dietary_Supplements
35. How Should Clinicians Respond to Patient Interest in Dietary Supplements to Treat Serious Chronic Illness? | Journal of Ethics, accessed October 1, 2025, https://journalofethics.ama-assn.org/article/how-should-clinicians-respond-patient-interest-dietary-supplements-treat-serious-chronic-illness/2022-05
36. Anti-ageing science: products ready for consumption? - CUHK Centre for Bioethics - The Chinese University of Hong Kong, accessed October 1, 2025, https://bioethics.med.cuhk.edu.hk/wp-content/uploads/2022/11/Revised_Anti-ageing-science_12-Jan-201821068.pdf
37. Investigating the Regulatory Process, Safety, Efficacy and Product Transparency for Nutraceuticals in the USA, Europe and Australia - MDPI, accessed October 1, 2025, https://www.mdpi.com/2304-8158/12/2/427